• Publications
  • Influence
Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly
  • A. Green
  • Medicine
  • British journal of pharmacology
  • 1 March 2008
It is suggested that animal models must be made more representative of the patient condition (with other co‐morbid conditions) and suggests that since stroke is primarily a cardiovascular disease with a neurological outcome, more research on the neurovascular unit would be valuable. Expand
The role of monoamines in the changes in body temperature induced by 3,4‐methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives
TheHyperthermia occurring in recreational users of MDMA can be fatal, but data reviewed here indicate that it is unlikely that any single pharmaceutical agent will be effective in reversing the hyperthermia, so careful body cooling remains the principal clinical approach. Expand
Lost in translation: preclinical studies on 3,4‐methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans
Observations question whether MDMA alone produces long‐term 5‐HT neurotoxicity in human brain, although when taken in combination with other recreational drugs it may induce neurotoxicity. Expand
Differential effects of cathinone compounds and MDMA on body temperature in the rat, and pharmacological characterization of mephedrone‐induced hypothermia
Recreational users report that mephedrone has similar psychoactive effects to 3,4‐methylenedioxymethamphetamine (MDMA), but there is little preclinical data on the acute effects of mePhedrone or other synthetic cathinones. Expand
Therapeutic strategies for the treatment of stroke.
There are a variety of new neuroprotective compounds in the early stages of investigation and some could prove clinically effective, provided appropriate preclinical development guidelines are observed. Expand
Effect of NXY‐059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window
The data demonstrate the substantial neuroprotective efficacy of N XY‐059 at plasma concentrations that can be achieved clinically and indicate that NXY‐059 also has a therapeutic window of opportunity that is clinically relevant. Expand
Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke
Investigation of the effect of the free radical trapping agent disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide on outcome following intracerebral hemorrhage in rat found that rats treated with NXY-059 had significantly decreased neurological impairment at all times. Expand
The preclinical pharmacology of mephedrone; not just MDMA by another name
Overall, current data suggest that mephedrone not only differs from MDMA in its pharmacological profile, behavioural and neurotoxic effects, but also differs from other cathinones. Expand
GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke
The evidence that GABAergic function is acutely depressed following an ischaemic insult is examined, and the data that suggest that increasing cerebral GABA concentration has a neuroprotective effect, as does the administration of some (but not all) GABAmimetic agents are reviewed. Expand
Effects of NXY‐059 in experimental stroke: an individual animal meta‐analysis
This first‐ever individual animal meta‐analysis was used to assess the preclinical studies of Disodium 2,4‐disulphophenyl‐N‐tert‐butylnitrone and found it to be neuroprotective in experimental stroke models but ineffective in a large clinical trial. Expand